ReviewInflammopharmacology2025
Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Epidermal Dominance of Metabolically Constrained Immune Niches Underpins Immune Activation Signatures and Clinical Severity in Psoriatic Disease.Immunology · 2026Article
- A spatial transit-retention axis reveals adaptive immune organisation in psoriatic disease.Molecular and cellular biochemistry · 2026Article
- Chimeric antigen receptor macrophage (CAR-M) immunotherapy in autoimmune inflammatory rheumatic diseases.Clinical rheumatology · 2026Review
- Platelet-neutrophil niches associate with epidermal immune activation and systemic inflammation in psoriatic disease.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Spatial Imbalance of Innate-like T-Cell Niches Underlies Clinical Trajectories in Psoriasis.International journal of molecular sciences · 2026Article
- Causal Relationship Between Psoriatic Arthritis and Coronary Heart Disease: A Mendelian Randomization and Bioinformatics Analysis.Psoriasis (Auckland, N.Z.) · 2026Article
- Therapeutic potential of Boswellia serrata in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFĸB modulation.Inflammopharmacology · 2025Review
- Editorial: Autoimmunity: novel insights and future perspectives.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA) is an immune-mediated, chronic inflammatory condition characterized by a complicated interplay between genetic, immunologic, and environmental determinants. The literature search was conducted using electronic databases including PubMed, Scopus, Web of Science, and Cochrane Library for articles published between 2010 and 2025. Keywords such as "Psoriatic Arthritis," "biologic therapies," "targeted treatments," and "clinical trends" were used with Boolean operators. Presenting in up to 30% of those with psoriasis, PsA involves joint inflammation, enthesitis, dactylitis, and skin and nail lesions and is commonly accompanied by comorbid conditions such as cardiovascular disease, metabolic syndrome, and depression. This review critically reviews the epidemiology, pathophysiology, clinical manifestations, and diagnostic modalities of PsA, including the role of genetic markers (e.g., HLA-B27, IL-23R), innate and adaptive immune dysregulation, and the emerging role of microbiome and epigenetic factors. Diagnostic approaches such as CASPAR criteria, imaging techniques, and novel biomarkers are discussed. The article also indicates current and developing management strategies, including the use of DMARDs, biologics, JAK inhibitors, and non-pharmacological interventions like exercise, diet, and patient education. Early recognition, tailored therapy, and the importance of a multidisciplinary team are stressed to improve patient outcomes and quality of life. Advances in targeted therapies and biomarker research are paving the way for more precise and effective PsA management.
Indexed as
Identifiers
40715930What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.